NEW YORK (TheStreet) -- Credit Suisse increased its price target on Amgen (AMGN) to $135, increased its estimates and set a "neutral" rating based on the company's new guidance in its second-quarter earnings report.
The stock was up 4.5% to $128.86 in pre-market trading on Wednesday.
Separately, TheStreet Ratings team rates AMGEN INC as a Buy with a ratings score of A+. TheStreet Ratings Team has this to say about their recommendation:
"We rate AMGEN INC (AMGN) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income."
You can view the full analysis from the report here: AMGN Ratings ReportAMGN data by YCharts